On January 6, 2020 Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, reported that Bing Wang, Ph.D., Co-Founder and Chief Executive Officer, will present a corporate update on Tuesday, January 14, 2020 at Biotech Showcase being held in San Francisco, from January 13-15, 2020 (Press release, Refuge Biotechnologies, JAN 6, 2020, View Source [SID1234552741]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The corporate presentation will focus on design of intelligent therapeutic cells by leveraging gene engineering technology called CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). Recent data supporting the company’s lead pipeline candidate, a HER2 CAR-T plus PD-1 knockdown system for various solid tumors, including head and neck, breast and gastrointestinal cancers will be shared.

Details of the presentation are as follows:

Date and Time: Tuesday, January 14, 2020 at 11:15 a.m. PT
Location: Hilton San Francisco Times Square
Track: Franciscan C (Ballroom Level)